Filtros de búsqueda

Lista de obras de

A further strategy to combat the high price of anticancer drugs

artículo científico publicado en 2017

ASCO Plenary Sessions: impact, legacy, future

artículo científico publicado en 2016

Accelerated single cell seeding in relapsed multiple myeloma

artículo científico publicado en 2020

Addendum: Low-value approvals and high prices might incentivize ineffective drug development

scientific article published on 01 December 2018

Affordable Care Act, Health Insurance Coverage, and Cancer Outcomes

artículo científico publicado en 2017

An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials

artículo científico publicado en 2016

Assessing Pharmaceutical Research and Development Costs-Reply

artículo científico publicado en 2018

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

scientific article published on 18 July 2019

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

scientific article published on 21 May 2019

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma

article

Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging

artículo científico publicado en 2015

CAR T and CAR NK cells in multiple myeloma: Expanding the targets

artículo científico publicado en 2020

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

artículo científico publicado en 2017

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers

artículo científico publicado en 2020

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers

artículo científico publicado en 2017

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

artículo científico publicado en 2017

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

scientific article published on 16 October 2019

Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease

artículo científico publicado en 2017

Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-Reply

artículo científico publicado en 2018

Clinically meaningful benefit: real world use compared against the American and European guidelines

artículo científico publicado en 2017

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

artículo científico publicado en 2018

Comparative Effectiveness Questions in Oncology

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma

scientific article published on 05 February 2020

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma

scientific article published on 11 December 2019

Controversies in multiple myeloma: Evidence-based update

artículo científico publicado en 2016

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma

artículo científico publicado en 2020

Dietary intake is associated with risk of multiple myeloma and its precursor disease

artículo científico publicado en 2018

Dilemmas in treating smoldering multiple myeloma

artículo científico publicado en 2014

Emerging immunotherapies in multiple myeloma

artículo científico publicado en 2020

Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation

artículo científico publicado en 2010

Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine

artículo científico publicado en 2015

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs

artículo científico publicado en 2015

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study

artículo científico publicado en 2018

Future of CAR T cells in multiple myeloma

artículo científico publicado en 2020

Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

artículo científico publicado en 2020

HIV, EBV, and monoclonal gammopathy

artículo científico publicado en 2013

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

scientific article published on 01 August 2020

Host-related immunodeficiency in the development of multiple myeloma.

artículo científico

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

artículo científico publicado en 2015

Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance

artículo científico publicado en 2017

Impact of genes highly correlated with MMSET myeloma on the survival of non-MMSET myeloma patients

artículo científico publicado en 2016

Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices

artículo científico publicado en 2016

Low-value approvals and high prices might incentivize ineffective drug development

scientific article published on 01 July 2018

MGUS prevalence in a cohort of AML patients

artículo científico publicado en 2013

Many Shades of Disparities in Myeloma Care

scientific article published on 01 January 2019

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

artículo científico publicado en 2015

Minimal residual disease: what are the minimum requirements?

artículo científico publicado en 2014

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma ⬇️

artículo científico publicado el 20 de octubre de 2010

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

scholarly article by Dickran Kazandjian et al published 4 February 2019 in Blood Cancer Journal

Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath

artículo científico publicado en 2018

Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia

artículo científico publicado en 2016

Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes

artículo científico publicado en 2018

Myeloma and second primary cancers

artículo científico publicado en 2011

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study

artículo científico publicado en 2017

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World

artículo científico publicado en 2017

Overall Survival vs Disease-Specific Survival-Reply

artículo científico publicado en 2017

Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement

artículo científico publicado en 2017

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2019

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

artículo científico publicado en 2016

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

artículo científico publicado en 2018

Pricing and Value of Cancer Drugs--Reply

artículo científico publicado en 2015

Proteomic profiling in plasma cell disorders: a feasibility study

artículo científico publicado en 2016

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

artículo científico publicado en 2018

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

artículo científico publicado en 2017

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.

artículo científico publicado en 2017

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) ⬇️

artículo científico publicado el 27 de julio de 2011

Second malignancies after multiple myeloma: from 1960s to 2010s ⬇️

artículo científico publicado el 6 de febrero de 2012

Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies

artículo científico publicado en 2014

Smoldering multiple myeloma: present position and potential promises

artículo científico publicado en 2013

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials

artículo científico publicado en 2014

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

scientific article published on 21 October 2019

Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma

artículo científico publicado en 2020

Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

artículo científico publicado en 2020

Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study

artículo científico publicado en 2015

Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute

artículo científico publicado en 2015

The Accelerated Approval of Oncologic Drugs

scientific article published in The Journal of the American Medical Association

The Effect of Neutropenia and Filgrastim (G-CSF) in Cancer Patients With COVID-19 Infection

artículo científico publicado en 2020

The Rising Price of Cancer Drugs-A New Old Problem?

artículo científico publicado en 2016

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma

artículo científico publicado en 2015

The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable

artículo científico publicado en 2016

The high price of anticancer drugs: origins, implications, barriers, solutions

artículo científico publicado en 2017

The road to treating smoldering multiple myeloma

artículo científico

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies

artículo científico publicado en 2016

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

artículo científico publicado en 2015

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood

artículo científico publicado en 2016

Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture

artículo científico publicado en 2014

Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda